FDA Decision on MDMA: What It Means for Patients and the Future of Therapy
The FDA rejected the registration of MDMA therapy in PTSD in August 2024. Check what the refusal was about, where the therapy is legal, and what happens next.
On August 9, 2024, the American FDA returned Lykos Therapeutics’ application for the approval of MDMA for the treatment of post-traumatic stress disorder. For patients who have followed a decade of clinical research, this sounded like a dead end. It was not. The refusal concerned one thing: the introduction of this therapy into circulation in the United States based on the data submitted up to that day. Research continues, access programs are operating in several countries, and psilocybin is following a separate registration pathway that has progressed further than MDMA by 2026. This text clarifies what exactly the refusal was about, what concerns the advisory committee raised, where patients can legally receive psychedelic therapy today, and what this means for readers in Poland.
KEY INFORMATION
• The FDA rejected the application for the registration of MDMA therapy in PTSD on August 9, 2024, and the analysis of this decision indicates that the main issue was its psychotherapeutic layer (Roseman, J Psychopharmacol, 2025).
• The refusal did not cover clinical trials or access programs; the agency requested another phase 3 study.
• Australia approved MDMA for PTSD and psilocybin for treatment-resistant depression from July 1, 2023, only through authorized psychiatrists.
• Canada has been conducting exceptional access since January 2022, and Israel has had a compassionate use program since February 2019.
• In the European Union, neither of these substances has permission for market approval.
What exactly did the FDA refusal concern, and what did it not?
The refusal letter (Complete Response Letter) from August 9, 2024, concerned one registration application: midomafetamine, or MDMA in capsules, as part of PTSD therapy conducted together with psychotherapy. The FDA did not stop clinical trials, did not close expanded access, and did not state that the substance is ineffective. It requested one thing: another phase 3 study.
This distinction has practical implications. A patient in the United States can still apply to participate in a clinical trial or for expanded access if they have exhausted standard therapeutic options. The pathway is narrow and requires the consent of both the study sponsor and the regulator, but it exists.
An analysis published in the Journal of Psychopharmacology points out a paradox that explains this refusal better than the dispute over the results themselves. Some of the FDA’s concerns related to psychotherapeutic and experiential elements, which the agency generally does not regulate. The author describes this as a tension between two models of thinking about a drug: the older one, in which the context of administration is a disturbance to be eliminated, and the newer one, in which the therapeutic effect arises from the interaction of the substance and the context (Roseman, J Psychopharmacol, 2025). We discuss the results of the registration studies more broadly in the text about phase 3 studies on MDMA in PTSD.
Why did the FDA advisory committee vote against it?
The advisory committee for psychopharmacological drugs met in June 2024 and expressed its opinion in two votes. On the efficacy of the therapy, nine members voted against, two in favor. On whether the benefits outweigh the risks under the proposed risk minimization plan, ten voted against, one in favor. The second result is sharper and less frequently cited.
The first concern was about blinding. In a study of a substance with such a clear subjective effect, most participants guess whether they received the drug or placebo. This phenomenon is called functional unblinding and undermines the comparison of groups because the participant’s expectations begin to co-create the outcome. The problem is not a regulator’s invention: it concerns every trial with a substance whose effects cannot be hidden from the subject, and it reappears in the assessment of ketamine just as with MDMA.
The second concern was about the conduct of therapeutic sessions and reports of violations in some centers. The third boiled down to a lack of data on how the therapy behaves outside the rigors of the research protocol. Why these three together were sufficient for refusal is broken down in a separate text about the reasons for the FDA’s refusal.
What does access to MDMA therapy look like in Australia?
Australia is the first country to allow both substances for clinical practice. The regulator (Therapeutic Goods Administration) announced the decision on February 3, 2023, and it came into effect on July 1, 2023. MDMA can be prescribed for PTSD from that day, and psilocybin for treatment-resistant depression.
The model is narrow and deliberately restricted. For these two indications, both substances were moved from the list of prohibited substances to the list of controlled drugs; their status did not change outside of this. They can only be prescribed by a psychiatrist who has obtained individual authorization from the regulator under the Authorised Prescriber scheme and the consent of the ethics committee. Sessions take place under supervision, in a facility, and not as a prescription to take home (TGA, 2023).
The therapy is not funded by public funds. The full program includes psychiatric qualification, preparatory sessions, supervised sessions, and integration meetings, all of which are paid for by the patient. This means that Australian access is legal but realistically applies to a small number of people. It should not be read as an example of therapy that is widely available.
Where else can psychedelic therapy be legally obtained today?
Outside of Australia, there are two other types of pathways: exceptional access for individual patients and compassionate use programs. Canada included psilocybin and MDMA in its Special Access Program in January 2022, allowing a physician to apply for the substance for a specific patient in a life-threatening situation or after exhausting other methods. Israel approved a compassionate use program for MDMA therapy in PTSD in February 2019, initially for fifty patients.
The following summary organizes the regulatory status in places that readers most frequently inquire about.
| Country or Region | MDMA in PTSD | Psilocybin | Esketamine |
|---|---|---|---|
| Australia | Approved since July 1, 2023, authorized psychiatrist | Approved for treatment-resistant depression, same date | Available |
| United States | FDA refusal letter, August 2024; expanded access | Phase 3 endpoints achieved, application announced | Approved since 2019 |
| Canada | Exceptional access since January 2022 | Exceptional access since January 2022 | Available |
| Israel | Compassionate use program since February 2019 | Clinical trials | Available |
| European Union and Poland | No approval, only clinical trials | No approval, studies ongoing | Drug program in Poland since July 1, 2023 |
A more comprehensive discussion of the disorders these therapies are currently being studied for can be found in the overview of therapies using psychedelics.
What about patients in Poland and Europe?
No EU country has approved MDMA or psilocybin for clinical practice outside of studies. The European Medicines Agency has not issued market approval for either, and in April 2024, it organized a workshop with researchers, regulators, and patient organizations specifically focused on what evidence is still lacking to evaluate such an application.
The only substance from this border approved in the EU is esketamine, sold under the name Spravato and registered since 2019 for treatment-resistant depression. It is worth clarifying a point that popular texts often confuse: esketamine is not a classical psychedelic. It acts through the NMDA receptor, not the serotonin 5-HT2A receptor, and is a derivative of a dissociative anesthetic. It shares with psychedelics a rapid antidepressant effect, not the mechanism.
In Poland, treatment with esketamine is available in a drug program launched on July 1, 2023, the first drug program in Polish psychiatry. It concerns treatment-resistant depression, not PTSD. A patient with PTSD has access to psychotherapy with proven efficacy and pharmacotherapy conducted by a psychiatrist. Separately, ketamine is administered outside of registration indications in private practices, which we discuss in the text about ketamine therapy in Poland.
What has changed since the FDA decision and what can be expected?
The most significant changes have occurred on the sponsor’s side. In August 2024, Lykos Therapeutics announced a reorganization and a reduction of about 75 percent of its workforce, and Rick Doblin, the founder of MAPS, left the company’s board. In October 2024, the company accepted the FDA’s position and announced a new phase 3 study along with an independent review of previous data. The date for resubmission has not been announced.
It is also worth clarifying the relationship between MAPS and Lykos, as it is sometimes described incorrectly. Lykos is not a separate company that split off in 2023. It is the former MAPS Public Benefit Corporation, renamed in January 2024 during a funding round, still capitalistically linked to MAPS.
Psilocybin has progressed further during this same time. Compass Pathways announced achieving the primary endpoint in the phase 3 COMP005 study, in which 258 participants with treatment-resistant depression were randomly assigned to a single dose of COMP360 or placebo; the difference between groups was 3.6 points on the depression symptom scale, with a p-value below 0.001. The second phase 3 study also achieved its endpoint, with a difference of 3.8 points. The company announced plans to submit a registration application in the fourth quarter of 2026. This is a separate substance and a separate pathway, so the refusal for MDMA does not block it.
Reading this dispute, we noticed its axis, which is easy to overlook in press reports. The regulatory agency evaluates the drug, and here the subject of the application was a drug inseparable from psychotherapy. Roseman’s analysis directly names this as a tension between two ways of thinking about evidence, rather than a simple dispute over data. If this diagnosis is accurate, another phase 3 study will not resolve the issue by itself until the way combined therapies are evaluated changes.
Frequently Asked Questions
Does the FDA’s refusal mean that MDMA therapy is ineffective?
No. The refusal letter from August 2024 states that the submitted data is insufficient for registration and requests another phase 3 study. The advisory committee’s concerns primarily related to blinding, the conduct of sessions, and a lack of data outside the research protocol.
Can a PTSD patient legally receive MDMA therapy today?
In Australia, yes, with a psychiatrist who has individual authorization from the regulator, since July 1, 2023. In Canada through special access, in Israel through a compassionate use program. In the United States, only in a clinical trial or through expanded access. In the European Union, only in studies.
How did the FDA advisory committee vote?
In June 2024, there were two votes. On the efficacy of the therapy, nine members voted against, two in favor. On whether the benefits outweigh the risks under the proposed risk minimization plan, ten voted against, one in favor. The committee’s votes are not formally binding on the agency.
What happened to Lykos Therapeutics after the refusal?
The company announced a reorganization in August 2024 and a reduction of about 75 percent of its workforce, and the founder of MAPS left its board. In October 2024, it accepted the FDA’s position and announced a new phase 3 study and an independent review of previous data. The date for resubmission was not provided.
Did the refusal for MDMA stop research on psilocybin?
No. It is a separate substance and a separate registration pathway. Compass Pathways announced achieving primary endpoints in two phase 3 studies on psilocybin in treatment-resistant depression and announced a registration application for the fourth quarter of 2026.
Is esketamine from Spravato a psychedelic?
Not in the classical sense. Esketamine acts through the NMDA receptor, not the serotonin 5-HT2A receptor, and is derived from a dissociative anesthetic. It has been approved in the European Union since 2019 for treatment-resistant depression, and in Poland, it has been included in a drug program since July 1, 2023.
When can we realistically expect the next FDA decision on MDMA?
A date cannot be provided because the sponsor has not announced the submission date. A new phase 3 study, along with preparation and analysis, usually takes several years, and the agency’s review of the application takes additional months. Any specific year mentioned today is an estimate, not a promise.
This article is for informational and educational purposes. It describes clinical trials in which the substance is administered under the supervision of a physician after participant qualification; using these conditions on one’s own does not replicate this. These substances are controlled in Poland under the Act on Counteracting Drug Addiction. If you have suicidal thoughts, call the free, 24-hour numbers 116 123 or 800 70 2222. In case of life-threatening situations: 112.
Author: Michał Waluk · Published: 2026-08-09 · Updated: 2026-08-16
